KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Sarepta Therapeutics (SRPT) EBITDA: 2012-2025

Historic EBITDA for Sarepta Therapeutics (SRPT) over the last 12 years, with Jun 2025 value amounting to -$447.3 million.

  • Sarepta Therapeutics' EBITDA fell 7406.91% to -$447.3 million in Q2 2025 from the same period last year, while for Jun 2025 it was -$242.6 million, marking a year-over-year decrease of 612.59%. This contributed to the annual value of $218.1 million for FY2024, which is 140.89% up from last year.
  • Sarepta Therapeutics' EBITDA amounted to -$447.3 million in Q2 2025, which was down 376.63% from $161.7 million recorded in Q4 2024.
  • In the past 5 years, Sarepta Therapeutics' EBITDA registered a high of $161.7 million during Q4 2024, and its lowest value of -$515.5 million during Q1 2023.
  • In the last 3 years, Sarepta Therapeutics' EBITDA had a median value of $6.1 million in 2024 and averaged -$82.4 million.
  • In the last 5 years, Sarepta Therapeutics' EBITDA soared by 242.46% in 2024 and then crashed by 7,406.91% in 2025.
  • Over the past 5 years, Sarepta Therapeutics' EBITDA (Quarterly) stood at -$122.0 million in 2021, then increased by 11.71% to -$107.7 million in 2022, then skyrocketed by 143.83% to $47.2 million in 2023, then surged by 242.46% to $161.7 million in 2024, then tumbled by 7,406.91% to -$447.3 million in 2025.
  • Its EBITDA stands at -$447.3 million for Q2 2025, versus $161.7 million for Q4 2024 and $36.9 million for Q3 2024.